{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:32:42Z","timestamp":1781195562131,"version":"3.54.1"},"reference-count":113,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI-086037"],"award-info":[{"award-number":["AI-086037"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI 101093"],"award-info":[{"award-number":["AI 101093"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI-48693"],"award-info":[{"award-number":["AI-48693"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI153830"],"award-info":[{"award-number":["R01AI153830"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jaip.2022.11.007","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T04:57:18Z","timestamp":1672894638000},"page":"107-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advances and Challenges of the Decade: The Ever-Changing Clinical and Genetic Landscape of Immunodeficiency"],"prefix":"10.1016","volume":"11","author":[{"given":"Jolan E.","family":"Walter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ballow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Cunningham-Rundles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.11.007_bib1","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0140-6736(72)92345-8","article-title":"Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity","volume":"2","author":"Giblett","year":"1972","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.11.007_bib2","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.1073\/pnas.80.24.7481","article-title":"Cloning of cDNA sequences of human adenosine deaminase","volume":"80","author":"Wiginton","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2022.11.007_bib3","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1073\/pnas.84.16.5947","article-title":"Mutations in the human adenosine deaminase gene that affect protein structure and RNA splicing","volume":"84","author":"Akeson","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2022.11.007_bib4","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0140-6736(75)91950-9","article-title":"Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity","volume":"1","author":"Giblett","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.11.007_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0092-8674(93)90167-O","article-title":"Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans","volume":"73","author":"Noguchi","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.jaip.2022.11.007_bib6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.jaip.2022.11.007_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2022.11.007_bib8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","article-title":"Initial sequencing and analysis of the human genome","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2022.11.007_bib9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10875-020-00758-x","article-title":"Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification","volume":"40","author":"Bousfiha","year":"2020","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10875-019-00737-x","article-title":"Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee","volume":"40","author":"Tangye","year":"2020","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abb1662","article-title":"Human inborn errors of immunity: an expanding universe","volume":"5","author":"Notarangelo","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib12","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","article-title":"DNA sequencing with chain-terminating inhibitors","volume":"74","author":"Sanger","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2022.11.007_bib13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1006\/abio.1996.0432","article-title":"Real-time DNA sequencing using detection of pyrophosphate release","volume":"242","author":"Ronaghi","year":"1996","journal-title":"Anal Biochem"},{"key":"10.1016\/j.jaip.2022.11.007_bib14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature03959","article-title":"Genome sequencing in microfabricated high-density picolitre reactors","volume":"437","author":"Margulies","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2022.11.007_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygeno.2015.11.003","article-title":"The sequence of sequencers: the history of sequencing DNA","volume":"107","author":"Heather","year":"2016","journal-title":"Genomics"},{"key":"10.1016\/j.jaip.2022.11.007_bib16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fimmu.2016.00220","article-title":"Genetic diagnosis using whole exome sequencing in common variable immunodeficiency","volume":"7","author":"Maffucci","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jaci.2016.05.042","article-title":"Primary immunodeficiency diseases: genomic approaches delineate heterogeneous Mendelian disorders","volume":"139","author":"Stray-Pedersen","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jmoldx.2022.02.007","article-title":"A\u00a0novel targeted amplicon next-generation sequencing gene panel for the diagnosis of common variable immunodeficiency has a high diagnostic yield: results from the Perth CVID cohort study","volume":"24","author":"Kermode","year":"2022","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.jaip.2022.11.007_bib19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41586-020-2265-1","article-title":"Whole-genome sequencing of a sporadic primary immunodeficiency cohort","volume":"583","author":"Thaventhiran","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2022.11.007_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.906540","article-title":"Global expansion of Jeffrey's Insights: Jeffrey Modell Foundation's genetic sequencing program for primary immunodeficiency","volume":"13","author":"Quinn","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.928062","article-title":"Secondary immune deficiency and primary immune deficiency crossovers: hematological malignancies and autoimmune diseases","volume":"13","author":"Ballow","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib22","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.jaip.2022.05.017","article-title":"Take a leap of faith: implement routine genetic testing in your office","volume":"10","author":"Convers","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.11.007_bib23","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jaci.2020.06.011","article-title":"The scary world of variants of uncertain significance (VUS): a hitchhiker's guide to interpretation","volume":"147","author":"Sullivan","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib24","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaci.2021.04.039","article-title":"Therapeutic options for CTLA-4 insufficiency","volume":"149","author":"Egg","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.648951","article-title":"Gene therapies for primary immune deficiencies","volume":"12","author":"Kohn","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib26","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.jaip.2022.04.001","article-title":"Atopy as immune dysregulation: offender genes and targets","volume":"10","author":"Vaseghi-Shanjani","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.11.007_bib27","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood-2011-09-377945","article-title":"Morbidity and mortality in common variable immune deficiency over 4 decades","volume":"119","author":"Resnick","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.11.007_bib28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood-2007-11-124545","article-title":"Common variable immunodeficiency disorders: division into distinct clinical phenotypes","volume":"112","author":"Chapel","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.11.007_bib29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fimmu.2020.00149","article-title":"Non-infectious complications of common variable immunodeficiency: updated clinical spectrum, sequelae, and insights to pathogenesis","volume":"11","author":"Ho","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10875-017-0456-9","article-title":"Autoimmune cytopenias and associated conditions in CVID: a report from the USIDNET registry","volume":"38","author":"Feuille","year":"2018","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib31","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jaci.2016.12.978","article-title":"Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies","volume":"140","author":"Fischer","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib32","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","article-title":"Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee","volume":"42","author":"Tangye","year":"2022","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib33","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1182\/blood.2019000929","article-title":"Current genetic landscape in common variable immune deficiency","volume":"135","author":"Abolhassani","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.11.007_bib34","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fimmu.2018.00636","article-title":"Evaluating the genetics of common variable immunodeficiency: monogenetic model and beyond","volume":"9","author":"de Valles-Ibanez","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.786516","article-title":"Establishing the molecular diagnoses in a cohort of 291 patients with predominantly antibody deficiency by targeted next-generation sequencing: experience from a monocentric study","volume":"12","author":"Rojas-Restrepo","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib36","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/ng1601","article-title":"TACI is mutant in common variable immunodeficiency and IgA deficiency","volume":"37","author":"Castigli","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaip.2022.11.007_bib37","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.jaci.2018.01.039","article-title":"Loss-of-function nuclear factor kappaB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans","volume":"142","author":"Tuijnenburg","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib38","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jaip.2022.11.007_bib39","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2022.11.007_bib40","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib41","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ajhg.2012.04.015","article-title":"Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity","volume":"90","author":"Lopez-Herrera","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaip.2022.11.007_bib42","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jaci.2019.12.896","article-title":"Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score","volume":"145","author":"Tesch","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib43","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood-2014-04-570101","article-title":"Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3","volume":"125","author":"Haapaniemi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.11.007_bib44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clim.2018.10.005","article-title":"Hypogammaglobulinemia\u00a0with decreased class-switched B-cells and dysregulated T-follicular-helper cells in IPEX syndrome","volume":"197","author":"Shamriz","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.857050","article-title":"Seeking relevant biomarkers in common variable immunodeficiency","volume":"13","author":"Ho","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib46","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.144777","article-title":"Circulating bioactive bacterial DNA is associated with immune activation and complications in common variable immunodeficiency","volume":"6","author":"Ho","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaip.2022.11.007_bib47","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jaci.2021.04.015","article-title":"Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations","volume":"148","author":"Thalhammer","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib48","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2015-11-679902","article-title":"Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype","volume":"127","author":"Toubiana","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.11.007_bib49","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jaip.2019.02.018","article-title":"Clinical aspects of STAT3 gain-of-function germline mutations: a systematic review","volume":"7","author":"Fabre","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.11.007_bib50","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib51","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jaci.2017.10.041","article-title":"Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: an international multicenter retrospective study","volume":"141","author":"Barzaghi","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib52","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/MOP.0000000000000833","article-title":"Autoimmunity as a continuum in primary immunodeficiency","volume":"31","author":"Walter","year":"2019","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.jaip.2022.11.007_bib53","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.jaip.2019.02.038","article-title":"Outcomes and treatment strategies for autoimmunity and hyperinflammation in patients with RAG deficiency","volume":"7","author":"Farmer","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.11.007_bib54","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jaci.2021.11.020","article-title":"The new quest in CTLA-4 insufficiency: how to immune modulate effectively?","volume":"149","author":"Westermann-Clark","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib55","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jaci.2017.05.022","article-title":"Exaggerated follicular helper T-cell responses in patients with LRBA deficiency caused by failure of CTLA4-mediated regulation","volume":"141","author":"Alroqi","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abh0891","article-title":"The expansion of human T-bet(high)CD21(low) B cells is T cell dependent","volume":"6","author":"Keller","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib57","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41590-022-01271-6","article-title":"Partial RAG deficiency in humans induces dysregulated peripheral lymphocyte development and humoral tolerance defect with accumulation of T-bet+ B cells","volume":"23","author":"Csomos","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib58","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jaci.2017.04.023","article-title":"Treatment of severe forms of LPS-responsive beige-like anchor protein deficiency with allogeneic hematopoietic stem cell transplantation","volume":"141","author":"Seidel","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib59","first-page":"313","article-title":"Familial lymphopenia with agammaglobulinemia & severe moniliasis: the essential lymphocytophthisis as a special form of early childhood agammaglobulinemia [in German]","volume":"13","author":"Tobler","year":"1958","journal-title":"Helv Paediatr Acta"},{"key":"10.1016\/j.jaip.2022.11.007_bib60","first-page":"79","article-title":"The Swiss type of agammaglobulinemia [in German]","volume":"27","author":"Hitzig","year":"1968","journal-title":"Ergeb Inn Med Kinderheilkd"},{"key":"10.1016\/j.jaip.2022.11.007_bib61","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0140-6736(68)92673-1","article-title":"Immunological reconstitution of sex-linked lymphopenic immunological deficiency","volume":"2","author":"Gatti","year":"1968","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.11.007_bib62","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1056\/NEJM200204183461612","article-title":"Successful gene therapy for severe combined immunodeficiency","volume":"346","author":"Rosen","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.11.007_bib63","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaci.2011.12.964","article-title":"The long quest for neonatal screening for severe combined immunodeficiency","volume":"129","author":"Buckley","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib64","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jpeds.2009.07.049","article-title":"Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis","volume":"155","author":"Railey","year":"2009","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jaip.2022.11.007_bib65","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2004.10.012","article-title":"Development of population-based newborn screening for severe combined immunodeficiency","volume":"115","author":"Chan","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib66","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/blood-2017-05-781849","article-title":"Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study","volume":"130","author":"Heimall","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.11.007_bib67","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1401177","article-title":"Transplantation outcomes for severe combined immunodeficiency, 2000-2009","volume":"371","author":"Pai","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.11.007_bib68","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2011.12.004","article-title":"The Wisconsin approach to newborn screening for severe combined immunodeficiency","volume":"129","author":"Verbsky","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib70","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaci.2011.12.964","article-title":"The long quest for neonatal screening for severe combined immunodeficiency","volume":"129","author":"Buckley","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib71","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.01.032","article-title":"Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles","volume":"129","author":"Puck","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib72","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jama.2014.9132","article-title":"Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States","volume":"312","author":"Kwan","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2022.11.007_bib74","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/ijns3020013","article-title":"Newborn screening for severe combined immunodeficiency in Israel","volume":"3","author":"Rechavi","year":"2017","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.jaip.2022.11.007_bib75","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/ijns8010004","article-title":"Study design for an evaluation of newborn screening for SCID in the UK","volume":"8","author":"Elliman","year":"2022","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.jaip.2022.11.007_bib76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/ijns7010015","article-title":"Neonatal screening in Europe revisited: an ISNS perspective on the current state and developments since 2010","volume":"7","author":"Loeber","year":"2021","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.jaip.2022.11.007_bib77","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/ijns8030044","article-title":"Economic evaluation of newborn screening for severe combined immunodeficiency","volume":"8","author":"Shih","year":"2022","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.jaip.2022.11.007_bib79","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1399-3038.2007.00646.x","article-title":"Contributors to the Australian Paediatric Surveillance U. Severe combined immunodeficiency: a national surveillance study","volume":"19","author":"Yee","year":"2008","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib80","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2018.08.027","article-title":"The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018)","volume":"143","author":"Dvorak","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.61","article-title":"Severe combined immunodeficiencies and related disorders","volume":"1","author":"Fischer","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaip.2022.11.007_bib82","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.jaci.2021.08.026","article-title":"Recommendations for uniform definitions used in newborn screening for severe combined immunodeficiency","volume":"149","author":"Blom","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib83","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1749-6632.2011.06241.x","article-title":"Newborn screening for SCID: three years of experience","volume":"1238","author":"Chase","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaip.2022.11.007_bib84","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/ijns4020019","article-title":"Development of a population-based newborn screening method for severe combined immunodeficiency in Manitoba, Canada","volume":"4","author":"Thompson","year":"2018","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.jaip.2022.11.007_bib85","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/ijns7040074","article-title":"Future perspectives of newborn screening for inborn errors of immunity","volume":"7","author":"Blom","year":"2021","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.jaip.2022.11.007_bib86","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jaci.2020.10.020","article-title":"SCID newborn screening: what we've learned","volume":"147","author":"Currier","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib87","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jaip.2021.02.006","article-title":"Ten years of newborn screening for severe combined immunodeficiency (SCID) in Massachusetts","volume":"9","author":"Hale","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.11.007_bib88","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.jaip.2022.04.013","article-title":"Lessons learned from five years of newborn screening for severe combined immunodeficiency in Israel","volume":"10","author":"Lev","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.11.007_bib89","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10875-014-0006-7","article-title":"Newborn screening for SCID in New York State: experience from the first two years","volume":"34","author":"Vogel","year":"2014","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib90","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaci.2013.04.024","article-title":"Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years","volume":"132","author":"Kwan","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib91","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10875-017-0388-4","article-title":"Immunodeficiencies associated with abnormal newborn screening for T cell and B cell lymphopenia","volume":"37","author":"Jyonouchi","year":"2017","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib92","doi-asserted-by":"crossref","first-page":"335ra357","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2022.11.007_bib93","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jaci.2016.07.040","article-title":"A\u00a0prospective study on the natural history of patients with profound combined immunodeficiency: an interim analysis","volume":"139","author":"Speckmann","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib94","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.jaci.2018.02.007","article-title":"Prevalence and clinical challenges among adults with primary immunodeficiency and recombination-activating gene deficiency","volume":"141","author":"Lawless","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib95","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3389\/fimmu.2020.01954","article-title":"Asymptomatic infant with atypical SCID and novel hypomorphic RAG variant identified by newborn screening: a diagnostic and treatment dilemma","volume":"11","author":"Chitty-Lopez","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib96","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","volume":"9","author":"Bruton","year":"1952","journal-title":"Agammaglobulinemia. Pediatrics"},{"key":"10.1016\/j.jaip.2022.11.007_bib97","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.iac.2008.01.008","article-title":"Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency","volume":"28","author":"Berger","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2022.11.007_bib98","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s10875-011-9588-5","article-title":"Efficacy and safety of subcutaneous vivaglobin replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study","volume":"31","author":"Borte","year":"2011","journal-title":"J\u00a0Clin Immunol"},{"issue":"suppl 3","key":"10.1016\/j.jaip.2022.11.007_bib99","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib100","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10875-012-9740-x","article-title":"Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again","volume":"32","author":"Wasserman","year":"2012","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib101","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.intimp.2005.11.004","article-title":"Safety considerations in IGIV utilization","volume":"6","author":"Siegel","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaip.2022.11.007_bib102","first-page":"518","article-title":"Renal insufficiency and failure associated with globulin intravenous therapy\u2014United States, 1985-1998","year":"1999","journal-title":"MMWR Morb Mortal Weekly Rep"},{"key":"10.1016\/j.jaip.2022.11.007_bib103","doi-asserted-by":"crossref","first-page":"E183","DOI":"10.1002\/ajh.26501","article-title":"Hemolysis after high-dose intravenous immunoglobulin: an under-appreciated sequelae","volume":"97","author":"Branch","year":"2022","journal-title":"Am J Hematol"},{"issue":"suppl 2","key":"10.1016\/j.jaip.2022.11.007_bib104","first-page":"S117","article-title":"Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products","volume":"55","author":"Hoefferer","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.jaip.2022.11.007_bib105","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.1002\/ajh.24644","article-title":"Association of immune globulin intravenous and thromboembolic adverse events","volume":"92","author":"Ovanesov","year":"2017","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"10.1016\/j.jaip.2022.11.007_bib106","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/cei.12518","article-title":"Adverse effects of immunoglobulin G therapy: thromboembolism and haemolysis","volume":"178","author":"Bonilla","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib107","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.tmrv.2020.06.003","article-title":"International survey of trials of convalescent plasma to treat COVID-19 infection","volume":"34","author":"Murphy","year":"2020","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jaip.2022.11.007_bib108","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe Covid-19 in older adults","volume":"384","author":"Libster","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.11.007_bib109","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jaci.2020.12.003","article-title":"Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2","volume":"147","author":"Ahn","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib110","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/infdis\/jiab142","article-title":"Rapidly increasing SARS-CoV-2 neutralization by intravenous immunoglobulins produced from plasma collected during the 2020 pandemic","volume":"226","author":"Farcet","year":"2022","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jaip.2022.11.007_bib111","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1473-3099(21)00059-1","article-title":"Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products","volume":"21","author":"Romero","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jaip.2022.11.007_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259731","article-title":"Modelling the concentration of anti-SARS-CoV-2 immunoglobulin G in intravenous immunoglobulin product batches","volume":"16","author":"Stinca","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2022.11.007_bib113","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/1744666X.2017.1389647","article-title":"RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations","volume":"13","author":"Wasserman","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib114","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3389\/fimmu.2015.00431","article-title":"Therapeutic immunoglobulin selected for high antibody titer to RSV also contains high antibody titers to other respiratory viruses","volume":"6","author":"Orange","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.11.007_bib115","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jama.2021.19994","article-title":"Realizing the potential of anti-SARS-CoV-2 monoclonal antibodies for COVID-19 management","volume":"327","author":"Li","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2022.11.007_bib116","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl8124","article-title":"The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans","volume":"14","author":"Loo","year":"2022","journal-title":"Sci Transl Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822011989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822011989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:36:47Z","timestamp":1761975407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822011989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":113,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2213219822011989"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.11.007","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances and Challenges of the Decade: The Ever-Changing Clinical and Genetic Landscape of Immunodeficiency","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}